Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

Intralesional triamcinolone is more effective than cryotherapy for treating alopecia areata in middle-aged adults.

Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

A man with X-ALD improved after treatment, highlighting the need to consider X-ALD in similar patients and test their relatives.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.

A quick method effectively detects banned substances in urine.

The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.

Placebo effects in alopecia treatments are likely due to study design, not real improvement.

IT PEP may help recovery after spinal cord injury, but more research is needed.

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

The conclusion is that the risk of losing significance in meta-analysis results increases with smaller effects and more missing data, and using the median standard deviation for imputation is recommended.

Combining treatments significantly reduces dark circles and wrinkles better than nanofat alone.

Well-designed clinical trials are needed to improve hair restoration methods.

1% minoxidil didn't improve hair growth for severe alopecia areata.

Measuring minimal residual disease on day 15 helps identify high-risk leukemia patients.

Translation can lead to misunderstandings in clinical research.

Orphan drug benefit scores in Germany are influenced by phase III data and lack of alternatives, but not linked to price or discounts.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

All HPV vaccine studies should be registered and published to reduce reporting bias.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.